Headed in the Right Direction But at Risk for Miscalculation A Critical Appraisal of the 2013 ACC/AHA Risk Assessment Guidelines by Amin, Nivee P. et al.
Journal of the American College of Cardiology Vol. 63, No. 25, 2014
 2014 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2014.04.010ViewpointHeaded in the Right Direction But
at Risk for Miscalculation
A Critical Appraisal of the
2013 ACC/AHA Risk Assessment Guidelines
Nivee P. Amin, MD, MHS,* Seth S. Martin, MD,* Michael J. Blaha, MD, MPH,*
Khurram Nasir, MD, MPH,*y Roger S. Blumenthal, MD,* Erin D. Michos, MD, MHS*
Baltimore, Maryland; and Miami Beach, FloridaTFrom the *Ciccaro
Hopkins Universit
Research, Baptist H
was received for th
by the Pollin Card
a pending patent
lipoprotein cholest
Pollin Professorshi
relationships releva
Manuscript recehe newly released 2013 ACC/AHA Guidelines for Assessing Cardiovascular Risk makes progress compared with
previous cardiovascular risk assessment algorithms. For example, the new focus on total atherosclerotic
cardiovascular diseases (ASCVD) is now inclusive of stroke in addition to hard coronary events, and there are now
separate equations to facilitate estimation of risk in non-Hispanic white and black individuals and separate
equations for women. Physicians may now estimate lifetime risk in addition to 10-year risk. Despite this progress,
the new risk equations do not appear to lead to signiﬁcantly better discrimination than older models. Because the
exact same risk factors are incorporated, using the new risk estimators may lead to inaccurate assessment of
atherosclerotic cardiovascular risk in special groups such as younger individuals with unique ASCVD risk factors. In
general, there appears to be an overestimation of risk when applied to modern populations with greater use of
preventive therapy, although the magnitude of overestimation remains unclear. Because absolute risk estimates are
directly used for treatment decisions in the new cholesterol guidelines, these issues could result in overuse of
pharmacologic management. The guidelines could provide clearer direction on which individuals would beneﬁt from
additional testing, such as coronary calcium scores, for more personalized preventive therapies. We applaud the
advances of these new guidelines, and we aim to critically appraise the applicability of the risk assessment tools
so that future iterations of the estimators can be improved to more accurately assess risk in individual patients.
(J Am Coll Cardiol 2014;63:2789–94) ª 2014 by the American College of Cardiology FoundationIn November 2013, the American College of Cardiology/
American Heart Association released new guidelines for
assessing cardiovascular risk (1). These risk assessment
guidelines (RAG) are an evolution from previous recom-
mendations that asymptomatic adults undergo a global risk
assessment as the ﬁrst step in the evaluation of atherosclerotic
cardiovascular disease (ASCVD) risk (2). Previous guidelines,
such as the Adult Treatment Panel III (ATP-III), used a
modiﬁed Framingham risk score (FRS) (3) to set thresholds
for lipid treatment based on one’s predicted 10-year risk for
myocardial infarction or coronary heart disease (CHD) death.
However, the FRS was limited by both underestimation (4–6)
and overestimation (7) of risk in different populations. Newer
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ived December 11, 2013; accepted April 9, 2014.(RRS) for ASCVD (8) and variations of the FRS developed
for total ASCVD, lifetime risk, and risk estimation without
laboratory results (9). With so many risk-scoring systems,
clinicians often ignored formal global risk assessment in
clinical practice (10) because it was challenging to know
which to use for each particular patient.
The RAG also endorse global risk assessment as a ﬁrst
step in asymptomatic adults age 40 to 79 years. New pooled
cohort equations (2013 Risk Models) estimate 10-year risk
for a ﬁrst hard ASCVD event, including CHD and stroke,
but not congestive heart failure or revascularization. These
risk equations were derived using pooled data from National
Heart, Lung, and Blood Institute (NHLBI)–funded cohorts
beyond the Framingham original and offspring cohorts, in-
cluding ARIC (Atherosclerosis Risk in Communities),
CHS (Cardiovascular Health Study), and CARDIA (Cor-
onary Artery Risk Development in Young Adults) cohorts.
Importantly, RAG support separate risk assessment equa-
tions by gender and for African-American populations.
Former guidelines had recommended the use of single risk
stratiﬁcation algorithms for all individuals regardless of race/
ethnicity, thereby potentially overestimating or under-
estimating risk in nonwhite populations.
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2790We applaud these incremental
advances of RAG, but we also
recognize limitations for its wide-
spread applicability and use. This
paper critically appraises RAG
and provides our view about
what could be improved in future
iterations of the guidelines.
Performance in
More Diverse and
Modern Populations
Despite having a separate score
by sex and race, the RAGcaution against applying this algorithm to groups that are
neither white nor black. This may result in overestimation
of ASCVD risk in groups such as Chinese/East-Asian
Americans and underestimation in American-Indians and
Americans of South Asian descent (11). One notable
absence from the pooled cohorts was MESA (Multi-Ethnic
Study of Atherosclerosis), which had not reached 10 years of
follow-up time at the time the 2013 risk models were
developed. This is disappointing because, by design, MESA
is the most diverse of the NHLBI-funded cohorts.
Furthermore, MESA’s important ﬁndings regarding the
added prognostic value for risk prediction conferred by
subclinical vascular disease testing was not considered for
inclusion in the model.
By design, the populations included were from a gener-
ation ago and were less diverse. Many population changes
have occurred since that time, with secular trends in-
volving smoking habits, trans-fat intake, and preventive
medications. While the “outcome” of the risk score has
evolved to include ASCVD events, the “input” variables for
the risk prediction model remain identical. If future iterations
of the guidelines continue to rely on older cohorts, priori-
tizing them as more representative of the natural history of
ASCVD, then we will become more and more disconnected
from the modern patients in our clinics, and have less ability
to incorporate new inputs in risk estimation simply because
they were not measured generations ago.
The RAG also acknowledge overestimation of risk when
the 2013 risk models were applied to 2 external validation
cohorts (MESA and REGARDS [Reasons for Geographic
and Racial Differences in Stroke]) and to contemporary data
from 2 of the derivation cohorts (ARIC/Framingham) (11).
However, overestimation was more pronounced at higher-
risk (a group above the risk-based treatment threshold) than
for lower-risk groups where there would be clinical concern
for over-treatment. Discrimination was also suboptimal,
with C statistics of 0.66 to 0.77 in women and 0.56 to 0.71
in men compared with 0.81 and 0.71 to 0.75 in the
respective derivation cohorts (11).
When the 2013 risk models were applied to 3 large-scale
primary prevention cohortsdWHS (Women’s HealthStudy), PHS (Physicians’ Health Study), and WHI
(Women’s Health Initiative observational study), there was
also overestimation of risk (12). Discrepancies may exist in
these particular cohorts because these were largely lower
risk white cohorts and because of different methods for risk
factor measurement. A ﬂurry of attention was immediately
drawn to this new estimator and the implication that more
patients would be considered for statin therapy. As a
counterpoint, the guideline writers noted that most of the
discordance was in those with >10% estimated 10-year risk,
and that the risk estimator does not prescribe statin therapy,
but rather serves as a starting point for a “risk discussion.”
Less discordance occurred in the middle risk groups of 5.0%
to 7.5% and 7.5% to 10.0%. Moreover, the older ATP-III
version of the FRS for hard CHD events was also previ-
ously shown to overestimate risk (7).
A subsequent re-analysis of REGARDS (13) suggested
that calibration was improved if 5-year modiﬁcations of
2013 risk models were applied only in a “clinically relevant
population”dthose age 40 to 75 years, without diabetes, not
taking statins, and with LDL-C levels of 70 to 189 mg/dl.
This was especially the case if Medicare claims ﬁles were used
as a form of active ascertainment to identify more events.
Unfortunately, these claims events were not adjudicated, and
data available for calibration with observed ASCVD events
in REGARDS was only through 5 years (i.e., not 10 years as
per risk estimator). Moreover, discrimination remained
suboptimal, with C-statistics of w0.7 (13).
Similarly, in a more recent comparison of the 2013 Risk
Models vs. ATP III versus European Society of Cardiology
guidelines among participants of the Rotterdam Study, a
European cohort (14), all 3 models showed poor calibration
(overestimation of risk compared to observed incidence of
events) and just moderate discrimination (C-statistics 0.67
to 0.77). However, using the 2013 risk models with the new
thresholds set in the treatment guidelines, more people
would be eligible for a patient-clinician discussion to
consider statin therapy.
Collectively, these studies seem to call for a continued
examination of the proper population from which to derive
risk equations, and critical evaluation of the continued use
of population-equations for estimating risk in individual
patients (15).
Exclusion of Family History in the Model
Family history, which is asked by virtually every clinician
conducting clinical risk assessments, was considered for in-
clusion in the 2013 risk models. However, it did not
adequately improve model prediction, likely because it was
not distinguished from a family history of premature CHD, a
well-established predictor of subsequent ASCVD events
(16). The RAG limit the use of family history to those
patients in whom there is uncertainty in the risk-based
treatment decision. This is a departure from ATP-III,
which considered a family history of premature CHD a
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factor by experts in the 2011 American Heart Association’s
Effectiveness-Based Guidelines for the Prevention of Car-
diovascular Disease in Women (17). Additionally, Canadian
Cardiovascular Society guidelines recommended that a per-
son’s estimated risk be doubled with a family history of
premature ASCVD (18). Integrating family history into a risk
estimator could facilitate its universal adoption, such as is
done with the Reynolds Risk Score (8). Preventive cardio-
vascular practice dictates that family history be included in
each patient’s clinical assessment of risk, and we anticipate that
future iterations of the RAG will need to more fully integrate
family history into risk assessment.
No Mention of Special Populations at Risk
Systemic autoimmune collagen vascular diseases, such as
lupus erythematosus and rheumatoid arthritis, are more
prevalent in women and have been shown to increase one’s
relative risk for ASCVD (19). Pre-eclampsia is indepen-
dently associated with an increased risk for ASCVD (20).
The 2011 AHA Women’s Guidelines consider these dis-
orders to be signiﬁcant risk factors for ASCVD, on par with
traditional risk factors such as smoking and hypertension
(17). Further, chronic kidney disease is considered to be a
risk equivalent on par with clinically manifest ASCVD and
diabetes.
It would be cumbersome and impractical to add these and
other unique risk factors to a universal risk prediction model.
However, physicians require further direction on how best
to categorize individuals with unique risk factors. It is
especially in this setting that further risk stratiﬁcation with
tests that inherently clarify individual risk (such as by using
imaging tests, for example coronary artery calcium [CAC]
scoring), may better delineate those who would most likely
beneﬁt from preventive therapies (15).
Inclusion of Stroke in Risk Score Outcome
Atherosclerotic stroke and CHD share many risk factors,
and it is commendable that the RAG also highlighted stroke
among its important ASCVD outcomes. However, only
w40% of strokes are from large vessel (i.e., carotid) ath-
erosclerotic disease; therefore, only this fraction is most
amenable to primary prevention with statin therapy. The
remainder of strokes are cardioembolic, lacunar, or hemor-
rhagic and unlikely to beneﬁt from statins (21,22). We
caution against extrapolating the ASCVD risk estimate to
determine statin eligibility given the diverse etiology of
“stroke.” It remains to be seen how well this risk threshold
will perform in discriminating who would best and least
beneﬁt from preventive therapy for stroke prevention, which
is a separate question than predicting global ASCVD risk.
The inclusion of stroke also makes the new risk estimator
much more sensitive to age, which was already perceived as a
possible weakness of the FRS. Because strokes are very rarein young patients, and nearly exclusively occur in older pa-
tients, risk with the new estimator rises much faster with age
compared to the FRS.
Lowering the High-Risk Threshold to ‡7.5%
The RAG now adopts a threshold of 7.5% 10-year
ASCVD risk to indicate “high-risk” status, and reference
is made to the 2013 Cholesterol Guidelines, which endorse
instituting statin treatment at this threshold after patient–
clinician discussion (1). In contrast, ATP-III categorized
10% to 20% as “intermediate risk” and 20% as high risk
(3). These risk percentages are not directly comparable, but
the newer measures will signiﬁcantly increase the number of
individuals potentially eligible for statin therapy. This is
especially true because persons with low-density lipoprotein
cholesterol levels previously characterized as normal (70 to
100 mg/dl) might now be considered for pharmacotherapy.
Many people will cross the 7.5% threshold on the basis of
chronologic age alone, a nonmodiﬁable risk factor. Nearly all
African-American men over age 62 years with ideal param-
eters would cross over the 7.5% threshold and be considered
for statin treatment. Risk equations apply to populations: no
single individual has a 7.5% 10-year risk. Therefore, without
personalized attention to the individual, patients may be
overtreated or undertreated (15). The estimators do not take
into account unique risk factors or “vascular age.” For example,
elderly individuals with no CAC actually have a lower mor-
tality than younger individuals with high CAC scores (23).
Previous guidelines have supported the use of additional
screening tests such as CAC in the “intermediate-risk” group
(10% to 20% 10-year risk) with a Class IIa indication and
with a Class IIb indication for 6% to 10% 10-year risk (2).
However, in the RAG, the new de facto “intermediate-risk”
category of 5.0% to 7.5% is now rather narrow (24). This
further minimizes the potential gains to be added by testing for
subclinical atherosclerosis. Furthermore, by putting more
people into low and high risk groups, the RAG gives the
appearance of greater certainty of risk, when in fact the 2013
risk models use the risk modeling techniques and same risk
factors as prior estimators (24).
Subclinical Atherosclerosis Assessment
The most signiﬁcant limitation of the RAG is a tepid
endorsement for the selective use of screening tests for
subclinical atherosclerosis. The new guidelines only give a
Class IIb indication for optional screening tests when risk-
based decisions are “uncertain.” Risk status may be upgraded
to a higher score if one of the following is present: family
history of premature ASCVD, high-sensitivity C-reactive
protein score 2.0 mg/l, CAC score 300 or 75th
percentile, or an ankle-brachial index <0.9. Carotid intima-
medial thickness alone was not recommended as a screening
tool. No guidance was given on how to use these tests to
downgrade risk estimates, although this may be one of best
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clarify in which patients risk is “uncertain.” Some analyses
have suggested that nearly all risk estimates based just on
one-time assessments of traditional risk factors are in some
ways “uncertain” (15). Using the new risk guidelines, pro-
viders and payers will likely ﬁnd it difﬁcult to discern and
defend which patients would most beneﬁt from additional
screening for subclinical atherosclerosis.
Patients with a family history of premature ASCVD,
metabolic syndrome, inﬂammatory disorders, or complicated
pregnancy history (i.e., pre-eclampsia, low birth weight in-
fants) might be good candidates for additional evaluation
for subclinical atherosclerosis, regardless of their RAG-
estimated risk. It is important to remember that not
everyone with a family history of premature ASCVD is at a
relatively high risk for a future ASCVD event, and some
parental history of ASCVD may have been confounded by
prior smoking, which was much more common in prior
generations. Additionally, patients with higher risk driven
solely or primarily by age may be good candidates for
additional evaluation that could lead to downgrading the risk
estimate (15).
Compared with traditional risk factors, CAC clearly im-
proves risk discrimination. For comparison, in MESA, the
area under the ROC curve for the prediction of CHD events
was 0.76 (95% conﬁdence interval: 0.72 to 0.79) using a
model with only traditional risk factors similar to those
factors in the 2013 risk models, but increased to 0.81 (95%
conﬁdence interval: 0.78 to 0.84) with the addition of CAC
(26). Individuals without risk factors but elevated CAC have
substantially higher event rates than those who have multi-
ple risk factors but no CAC (27,28). In the MESA, in-
dividuals with 0 risk factors and CAC >300 had an event rate
3.5 times higher than individuals with 3 risk factors and
CAC of 0 (28). Similar ﬁndings were seen when CAC was
compared across FRS categories (28). When compared head-
to-head in the same population, CAC was a much more
potent risk discriminator than high-sensitivity C-reactive
protein (29), with far superior net reclassiﬁcation (26).
Individuals with CAC of 0 but elevated global risk score
(above the 7.5% threshold) may be prone to overtreatment
with pharmacologic therapies. Individuals with CAC of
0 have very low event rates (25,29,30); thus, the number
needed to treat to prevent 1 event with statin therapy may be
prohibitively high in this group. This raises the need for a
paradigm shift away from a predominantly risk factors–based
prevention approach for determining high risk, towards an
approach guided by the detection of subclinical atheroscle-
rosis for additional identiﬁcation of patients unlikely to gain
a new beneﬁt of treatment (31).
The threshold of a CAC score of >300 is also quite high,
consistent with advanced plaque. High event rates similar to
rates in secondary prevention populations have been noted
for CAC scores >100 (29,32), and that alternate threshold
may also be considered for determining eligibility for statin
therapy. Furthermore, a CAC >75th percentile score doesnot confer the same very high risk status as a score >300 or
>100, although these are viewed as equivalent options in the
RAG. For predicting 5-year event rates, absolute CAC
scores are superior to percentile scores (33).
The RAG did acknowledge that among additional
screening tests, CAC would be the most useful for im-
proving risk prediction. Their decision against incorpo-
rating CAC was based on a systematic review of subclinical
atherosclerosis markers (34) where the outcomes were CHD
events but not total ASCVD. However, in the Heinz Nix-
dorf Recall Study, CAC also predicted the risk of stroke
(35). In MESA, CAC predicts both CHD and total
ASCVD, although it was stronger for CHD (29).
The RAG further cite issues with cost and radiation as
reasons against a stronger endorsement for CAC. The cost
of CAC screening is now commonly $75 to $100, and less
expensive than certain diagnostic tests or years of treatment
with generic statin therapy. The radiation dose is down to
w1 mSv, comparable to a bilateral mammogram, which
is already an accepted screening tool (36). The EISNER
(Early Identiﬁcation of Subclinical Atherosclerosis by
Noninvasive Imaging Research) study showed that down-
stream costs were not increased with CAC screening, and
subsequent testing and treatment costs were reduced for
those found to have CAC scores of 0 (36).
10-Year Risk Versus Lifetime Risk
The RAG give a modest Class IIb indication for assessing a
30-year or lifetime ASCVD risk based on traditional risk
factors for adults age 20 to 59 years not at increased 10-year
risk. This will help in additional risk assessment for
younger individuals who may face unique risks. Individuals
with low 10-year but high lifetime risk have a greater sub-
clinical disease burden and greater incidence of atheroscle-
rotic progression compared with individuals with low
10-year and low lifetime risk, even at younger ages (37).
Differences in risk factor burden in middle age translate to
substantial differences in longevity and lifetime risk of
ASCVD (38). Assessment of lifetime risk may inﬂuence
physician behavior in recommending pharmacologic pre-
ventive therapies (39).
Conclusions
Thenew10-year pooledASCVDrisk scorewith sex- and race-
speciﬁc equations is an incremental improvement from the
ATP-III version using the 10-year FRS for hard CHD.
However, it will only be considered an overall improvement if
it leads to more personalized risk estimates, rather than less
personalized risk estimates. The RAG still need further
reﬁnement in their application for ethnically diverse pop-
ulations and younger individuals with unique cardiovascular
risk factors. In the next iterations, we would encourage a
thorough rethinking of the traditional approach to risk assess-
ment, with careful consideration of the interplay between a
risk-factor based model and an atherosclerosis imaging-based
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screening for subclinical atherosclerosis. As with any risk
model, the discussion and use of the information should be
individualized. We would like to see more explicit guidance
on how to best conduct a “risk discussion” in busy clinical
practice. We commend the advances made with the most
recent 2013 risk models, and we intend our constructive crit-
icism to serve as a starting point for further reﬁnement of
the RAG.
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